Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
Status:
Withdrawn
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the efficacy and safety of lenvatinib plus
nivolumab compared with lenvatinib monotherapy for patients with advanced hepatitis B virus
infection-related hepatocellular carcinoma.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Shi Ming
Collaborators:
First Affiliated Hospital, Sun Yat-Sen University Guangdong Provincial People's Hospital Guangzhou No.12 People's Hospital Third Affiliated Hospital, Sun Yat-Sen University